Epigenomics AG is a molecular diagnostics firm specializing in non-invasive liquid biopsy methods to identify cancer at its earliest stages. Their flagship offering, Epi proColon, is a blood test designed for the timely screening of colorectal cancer and is available across the United States, Europe, and China. The company's portfolio also includes a blood test for hepatocellular carcinoma, alongside Epi BiSKit, a pre-analytical solution comprising reagents essential for preparing bisulfite-converted DNA.